CONIC-TOTAL Trial Results and Impact on Sensitive Areas in Psoriasis

Patients with scalp psoriasis experienced significant improvement in the ICONIC-TOTAL studies, with approximately two-thirds achieving clear or almost clear scalp at 16 weeks of icotrokinra treatment. Individuals entering the trial with moderate to severe scalp involvement found substantial relief from persistent itching, flaking, and visible scaling that had previously affected their daily interactions and self-confidence. The oral treatment eliminated the need for topical scalp applications that many patients find messy, inconvenient, or ineffective.

Patients with genital psoriasis, representing about one-third of individuals with psoriasis, achieved clear or almost clear genital area involvement in 77% of cases at 16 weeks. This high-impact area significantly affects patients’ intimate relationships and overall quality of life, often causing embarrassment that prevents individuals from discussing the condition with health care providers. The remarkable response rates provide substantial relief for patients dealing with this sensitive area of involvement, which profoundly impacts personal relationships and emotional well-being.

Patients benefit from oral treatment that eliminates the challenges of applying topical medications to sensitive, hard-to-reach, or highly visible areas, such as the scalp and genital region. Many individuals prefer oral therapy to avoid the inconvenience, messiness, or inadequate coverage associated with topical treatments in these areas. The oral approach provides comprehensive treatment without requiring patients to navigate complex topical application routines or worry about product visibility in hair or intimate areas.